Shares trading at $2.25
SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome
FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors
SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome September 29, 2023
FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors September 28, 2023